GlassScriptPhysician profile
John F Kasper
NPI 1205842473
$7,029.12
in general payments reported to CMS, 2019-2025
28 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $1,053 · 2021: $1,400 · 2022: $1,054 · 2023: $1,011 · 2024: $618 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,507.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $851.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $722.89 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $703.40 | 2020-2025 | |
| Novo Nordisk INC | $650.23 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $596.98 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Aimmune Therapeutics, INC. | $327.61 | 2024-2025 | Zenpep |
| Pfizer INC. | $267.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $200.34 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $168.04 | 2019-2024 | Eliquis |
| Allergan, INC. | $152.34 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $149.20 | 2020-2022 | |
| Amarin Pharma, INC. | $115.81 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $97.51 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $81.01 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.71 | 2020-2023 | Jardiance |
| Exact Sciences Corporation | $51.89 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $47.42 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $47.22 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $39.29 | 2020 | |
| Currax Pharmaceuticals LLC | $37.31 | 2020 | |
| Eisai INC. | $29.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.23 | 2019-2021 | |
| Sanofi Pasteur INC. | $25.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.09 | 2019 | |
| Esperion Therapeutics, INC. | $13.53 | 2020 | |
| Abiomed | $13.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.